Eagle Pharmaceuticals, Inc. (EGRX) Analysts See $0.81 EPS; Principal Financial Group Has Decreased Ameren (AEE) Stake

April 23, 2018 - By David King

Principal Financial Group Inc decreased Ameren Corp (AEE) stake by 7.18% reported in 2017Q4 SEC filing. Principal Financial Group Inc sold 50,275 shares as Ameren Corp (AEE)’s stock declined 4.79%. The Principal Financial Group Inc holds 649,505 shares with $38.32 million value, down from 699,780 last quarter. Ameren Corp now has $13.78 billion valuation. The stock increased 0.60% or $0.34 during the last trading session, reaching $56.61. About 888,039 shares traded. Ameren Corporation (NYSE:AEE) has declined 0.30% since April 23, 2017 and is downtrending. It has underperformed by 11.85% the S&P500.

Analysts expect Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) to report $0.81 EPS on May, 14.They anticipate $0.61 EPS change or 42.96% from last quarter’s $1.42 EPS. EGRX’s profit would be $12.04 million giving it 16.95 P/E if the $0.81 EPS is correct. After having $0.84 EPS previously, Eagle Pharmaceuticals, Inc.’s analysts see -3.57% EPS growth. The stock decreased 0.04% or $0.02 during the last trading session, reaching $54.92. About 38,456 shares traded. Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has declined 36.05% since April 23, 2017 and is downtrending. It has underperformed by 47.60% the S&P500.

Among 9 analysts covering Ameren (NYSE:AEE), 3 have Buy rating, 2 Sell and 4 Hold. Therefore 33% are positive. Ameren had 25 analyst reports since July 28, 2015 according to SRatingsIntel. Barclays Capital downgraded the shares of AEE in report on Thursday, May 25 to “Equal-Weight” rating. The stock has “Hold” rating by Bank of America on Tuesday, October 24. Morgan Stanley maintained the stock with “Equal-Weight” rating in Friday, September 8 report. The firm has “Underweight” rating given on Wednesday, December 13 by Morgan Stanley. The company was maintained on Monday, April 16 by Morgan Stanley. The company was maintained on Tuesday, February 13 by Morgan Stanley. On Wednesday, October 18 the stock rating was maintained by KeyBanc Capital Markets with “Hold”. Morgan Stanley maintained it with “Overweight” rating and $57 target in Thursday, August 10 report. The stock of Ameren Corporation (NYSE:AEE) has “Neutral” rating given on Tuesday, July 28 by Goldman Sachs. The stock of Ameren Corporation (NYSE:AEE) has “Overweight” rating given on Monday, May 16 by Barclays Capital.

Since February 28, 2018, it had 0 insider buys, and 4 sales for $1.00 million activity. 1,952 Ameren Corporation (NYSE:AEE) shares with value of $105,955 were sold by Steinke Bruce A. The insider Lindgren Mark C sold $104,380. 1,462 shares were sold by NELSON GREGORY L, worth $79,357 on Wednesday, February 28. LYONS MARTIN J sold $714,812 worth of Ameren Corporation (NYSE:AEE) on Wednesday, February 28.

Investors sentiment increased to 1.16 in Q4 2017. Its up 0.03, from 1.13 in 2017Q3. It increased, as 37 investors sold AEE shares while 140 reduced holdings. 54 funds opened positions while 152 raised stakes. 165.76 million shares or 1.13% less from 167.66 million shares in 2017Q3 were reported. Principal Gp owns 0.04% invested in Ameren Corporation (NYSE:AEE) for 649,505 shares. Ferguson Wellman Capital Mngmt, a Oregon-based fund reported 49,928 shares. Mutual Of America Ltd Llc holds 0.05% of its portfolio in Ameren Corporation (NYSE:AEE) for 55,399 shares. First Quadrant Lp Ca has 230,857 shares. Utd Automobile Association holds 771,571 shares. Riverhead Capital Management Limited Liability Corporation has invested 0.18% in Ameren Corporation (NYSE:AEE). The Germany-based Dekabank Deutsche Girozentrale has invested 0.26% in Ameren Corporation (NYSE:AEE). Northwestern Mutual Wealth Management Communications has invested 0% of its portfolio in Ameren Corporation (NYSE:AEE). 30,900 were reported by Brookfield Asset Mgmt. Cleararc reported 0.05% of its portfolio in Ameren Corporation (NYSE:AEE). Advantus Mgmt holds 0.04% or 24,273 shares. Mason Street Advsrs Limited Liability Co holds 33,797 shares or 0.05% of its portfolio. Bnp Paribas Arbitrage Sa reported 235,764 shares. Inv Svcs Inc reported 0.45% of its portfolio in Ameren Corporation (NYSE:AEE). Millennium Mgmt Ltd Company holds 0.16% or 1.98 million shares.

Analysts await Ameren Corporation (NYSE:AEE) to report earnings on May, 3. They expect $0.58 EPS, up 38.10% or $0.16 from last year’s $0.42 per share. AEE’s profit will be $141.14 million for 24.40 P/E if the $0.58 EPS becomes a reality. After $0.39 actual EPS reported by Ameren Corporation for the previous quarter, Wall Street now forecasts 48.72% EPS growth.

Principal Financial Group Inc increased Pacific Premier Bancorp (NASDAQ:PPBI) stake by 270,153 shares to 290,287 valued at $11.61M in 2017Q4. It also upped Symantec Corp (NASDAQ:SYMC) stake by 20,694 shares and now owns 903,533 shares. Control4 Corp (NASDAQ:CTRL) was raised too.

Among 4 analysts covering Eagle Pharma (NASDAQ:EGRX), 3 have Buy rating, 1 Sell and 0 Hold. Therefore 75% are positive. Eagle Pharma had 24 analyst reports since July 29, 2015 according to SRatingsIntel. Piper Jaffray maintained the stock with “Buy” rating in Tuesday, January 30 report. Mizuho downgraded the stock to “Underperform” rating in Monday, January 9 report. RBC Capital Markets maintained Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) on Monday, February 26 with “Buy” rating. Piper Jaffray maintained it with “Overweight” rating and $119 target in Wednesday, July 29 report. On Wednesday, December 9 the stock rating was initiated by Mizuho with “Buy”. Mizuho maintained Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) on Wednesday, October 26 with “Buy” rating. The company was upgraded on Thursday, November 3 by Mizuho. On Friday, September 1 the stock rating was maintained by RBC Capital Markets with “Buy”. The stock of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) earned “Sell” rating by Mizuho on Wednesday, August 9. The company was maintained on Friday, July 14 by RBC Capital Markets.

Ameren Corporation (NYSE:AEE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.